JNJ vs MCK
JNJ: A diversified healthcare giant producing pharmaceuticals, medical devices, and consumer health products with a focus on innovation-driven therapeutic breakthroughs across oncology, immunology, infectious disease, and cardiovascular markets. MCK: McKesson is a healthcare services giant that orchestrates the entire pharmaceutical and medical supply chain—from drug distribution and specialty oncology care to technology platforms that connect patients, pharmacies, and providers.
Side-by-side fundamentals
| Metric | JNJ | MCK | Edge |
|---|---|---|---|
| Price as of 2026-07-09 close | $259.10 | $792.81 | |
| Market cap as of 2026-07-10 | $625.8B | $92.8B | |
| P/E as of 2026-07-10 | 29.74 | 19.48 | MCK lower |
| PEG as of 2026-07-10 | 3.16 | 1.50 | MCK lower |
| Net margin as of 2026-07-10 | +21.8% | +1.2% | JNJ higher |
| Gross margin as of 2026-07-10 | +68.0% | +3.6% | JNJ higher |
| Operating margin as of 2026-07-10 | +25.9% | +1.5% | JNJ higher |
| ROE as of 2026-07-10 | +26.3% | +39.4% | MCK higher |
| ROA as of 2026-07-10 | +10.7% | +5.7% | JNJ higher |
| Debt / equity as of 2026-07-10 | 0.68 | 1.29 | JNJ lower |
| Revenue growth (YoY) as of 2026-07-10 | +7.9% | +12.4% | MCK higher |
| Revenue CAGR (3y) SEC XBRL | +6.2% | +13.4% | MCK higher |
| Dividend yield as of 2026-07-10 | +2.1% | +0.4% | JNJ higher |
| Dividend streak (yrs) SEC XBRL | 5 | 5 | Tie |
| Beta as of 2026-07-10 | 0.23 | 0.33 | |
| 1-year return as of 2026-07-09 close | +65.8% | +9.0% | JNJ higher |
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.